[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@_OliverVenture Avatar @_OliverVenture Oliver Venture

Oliver Venture posts on X about $nams, $ntla, $beam, palantir the most. They currently have XXXXX followers and XX posts still getting attention that total XXX engagements in the last XX hours.

Engagements: XXX #

Engagements Line Chart

Mentions: XX #

Mentions Line Chart

Followers: XXXXX #

Followers Line Chart

CreatorRank: XXXXXXXXX #

CreatorRank Line Chart

Social Influence #

Social category influence stocks XXX% cryptocurrencies XXXX% technology brands XXXX% travel destinations XXXX% finance XXXX%

Social topic influence $nams #1, $ntla #12, $beam #22, palantir 2.04%, $abcl 2.04%, $pltr 2.04%, $odd #12, $tost 2.04%, $arkg 2.04%, $prme XXXX%

Top accounts mentioned or mentioned by @longoption @jessiechimni @planetoptimism @biomedicalrx @bigfatsurprise @corbeiljb @templedietitian @bulkbiker @bukvarevicedim @smartfinapp @samdavisesq @ny1972_47 @quartrapp @kendberrymd @fitfounder @pierrekory @midwesterndoc @drmakaryfda @megynkelly @marion436842126

Top assets mentioned NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) Intellia Therapeutics, Inc (NTLA) BEAM (BEAM) Palantir (PLTR) ODDITY Tech Ltd. Class A Ordinary Shares (ODD) Toast, Inc. (TOST) Certara, Inc. Common Stock (CERT) Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) Schrodinger, Inc. Common Stock (SDGR) Muhdo Hub (DNA) Bitcoin Incognito (XBI) Rubrik, Inc. (RBRK) Affirm Holdings, Inc. Class A Common Stock (AFRM) Pagaya Technologies Ltd. Class A Ordinary Shares (PGY) Global-E Online Ltd. Ordinary Shares (GLBE) CRISPR Therapeutics AG (CRSP) Hims & Hers Health, Inc. (HIMS)

Top Social Posts #

Top posts by engagements in the last XX hours

"Every time the Palantir guy says Abcellera $ABCL is the "$PLTR of Biotech" I have to go back do X days of research and re-conclude that yes Abcellera could be a Palantir of Biotech more than Absci $ABSI I think but with the handicap of lack of resources and long long time frames"
X Link @_OliverVenture 2025-10-04T15:57Z 1394 followers, 3898 engagements

"$ODD A recent addition the premise is simple: 🐻The market sees makeup fashion fads and competition. 🐂The reality is a company leveraging a data lake of billions of data points courtesy of AI and XX million users. Makeup was just step one. The real product is the repeatable (now proven) data-driven process for building new brands. ⚡This morning Oddity released strong and IMO unsurprising earnings assuming you've listened to literally any other previous call. but. Oddity oddly tanked because of . EBITDA margins CFO Lindsay Drucker Mann: "Adjusted EBITDA margin of XXXX% compressed by around"
X Link @_OliverVenture 2025-08-06T01:46Z 1394 followers, XXX engagements

"Ranking "The Palantir of Biotech" (or adjacent) in order of closest to something like a $PLTR model it's a stretch I know X. Recursion $RXRX X. Abcellera $ABCL X. Schrdinger $SDGR X. Relay $RLAY X. Ginkgo $DNA X. Certara $CERT Completely unclear: the benefit of being the PLTR of $XBI given the comically long timeframes (imagine $PLTR's business over the same timeframe it takes a company to move a program from discovery to approval: 10-15 years. Cut in half if you want still absurd)"
X Link @_OliverVenture 2025-10-05T20:29Z 1394 followers, 2631 engagements

"Condensed and added into recent weakness. $TOST $RBRK $AFRM $PGY $GLBE"
X Link @_OliverVenture 2025-09-30T21:41Z 1394 followers, XXX engagements

"$ARKG #CRISPR $NTLA $BEAM $CRSP $PRME Dude we're not even at '24 levels let alone 2020-21"
X Link @_OliverVenture 2025-10-12T23:20Z 1394 followers, 1222 engagements

"$NAMS why the stock didn't move. X. Preventive neurology is not (barely) a thing. X. P-tau217 is not a biomarker the FDA will accept as a single surrogate endpoint minus cognitive outcome data (which would take too long). X. Thus the path and timeline for an AD indication appears to be long expensive and uncertain. why it should move: X. The reduction in p-tau217 for the most at-risk cohort from obicetrapib was "comparable to that seen with anti-amyloid monoclonal antibodies in interventional trials." except achieved with a low dose pill with a well established safety profile remarkably"
X Link @_OliverVenture 2025-08-01T01:54Z 1394 followers, XXX engagements

"This is crazy. $NAMS"
X Link @_OliverVenture 2025-07-30T23:24Z 1394 followers, 2571 engagements

"Portfolio is having a totally normal one today. $SANA $HIMS $NTLA $NAMS $BEAM"
X Link @_OliverVenture 2025-10-15T18:56Z 1394 followers, XXX engagements

"$NAMS Everyone rotating into (checks notes) CETP inhibitors today. 😆"
X Link @_OliverVenture 2025-10-10T20:09Z 1394 followers, XXX engagements

"$NAMS New Amsterdam Pharma hit all time highs. XXX% gain for a moment. Not bad for (checks notes) a CETP inhibitor"
X Link @_OliverVenture 2025-10-06T14:01Z 1394 followers, 1331 engagements

"$NAMS "I and my colleagues also I don't think we expected such a huge effect that we are now observing. That combined with the fact that this is an absolute safe drug has been tested in so many patients already and has no significant side effects really opens the door to thinking about the application of obacitropib at a very early stage in people who carry the APOE4 gene who have the highest risk for for progression and developing AD at a very early stage to take obicetrapib delay the onset of AD pathology delay the onset of dementia symptoms and dependence on others." One of the KOLs from"
X Link @_OliverVenture 2025-07-30T18:36Z 1394 followers, XXX engagements

"$TOST is currently down -X% on news of price reductions on starter kits aimed at smaller restaurants. Toast scales its core business by winning new locations and the company believes they're in the early stages of capturing its addressable market claiming XX% ATM of the U.S. restaurant market. Market share is essential for the flywheel effects (density brand awareness scaling higher rep productivity) that drive Toast's sustained growth/record net locations. So yes this aligns with the company's core strategy but is at odds with: a) the bullish thesis and analyst fetish around Toast's upmarket"
X Link @_OliverVenture 2025-09-22T18:28Z 1394 followers, XXX engagements

"The good news is quality CRISPR stocks are getting the respect they deserve. The problem is every stock is going up so that isn't XXX% true. $ARKG $NTLA $BEAM $PRME $EDIT"
X Link @_OliverVenture 2025-10-08T22:28Z 1394 followers, 3346 engagements

"@BukvarevicEdim @bigfatsurprise No literally less than 10%. XX% following the standard american diet or worse (keto carnivore etc)"
X Link @_OliverVenture 2025-10-15T19:15Z 1394 followers, XX engagements

"Added to $ODD position"
X Link @_OliverVenture 2025-10-09T18:13Z 1394 followers, XXX engagements